DL-TBOA|cas:205309-81-5|西域试剂

DL-TBOA,99.68%

产品编号：Bellancom-107522| CAS NO：205309-81-5| 分子式：C₁₁H₁₃NO₅| 分子量：239.22

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-107522		￥2900.00	杭州北京（现货）
Bellancom-107522		￥4500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DL-TBOA

产品介绍

DL-TBOA 是一种有效的不可运输的兴奋性氨基酸转运蛋白抑制剂，对兴奋性氨基酸转运蛋白 1 (EAAT1)，EAAT2 和 EAAT3 的 IC₅₀ 值分别为 70 μM，6 μM 和 6 μM。DL-TBOA 抑制表达人 EAAT1 和 EAAT2 的 COS-1 细胞摄取 [¹⁴C]谷氨酸，K_i 值分别为 42 μM 和 5.7 μM。DL-TBOA 以竞争性方式阻断 EAAT4 和 EAAT5，K_i 值分别为 4.4 μM 和 3.2 μM。

生物活性

DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC₅₀s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), EAAT2 and EAAT3, respectively. DL-TBOA inhibits the uptake of [¹⁴C]glutamate in COS-1 cells expressing the human EAAT1 and EAAT2 with K_i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks EAAT4 and EAAT5 in a competitive manner with K_i values of 4.4 μM and 3.2 μM, respectively.

体外研究

DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability^[4].
DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	HCT116 and LoVo cell lines
Concentration:	70 μM, 350 μM
Incubation Time:	48 hours
Result:	Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death.

Cell Viability Assay^[4]

Cell Line:	HCT116 and LoVo cell lines
Concentration:	350 μM
Incubation Time:	24 hours
Result:	p53 induction by SN38 and oxaliplatin was decreased.

体内研究
(In Vivo)

DL-TBOA (10 nmol; i.c.v., rats) significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (180-250 g)^[5]
Dosage:	1 nmol, 3 nmol, 10 nmol
Administration:	Intracerebroventricularly injection (i.c.v.)
Result:	Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg).

体内研究

DL-TBOA (10 nmol; i.c.v., rats) significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (180-250 g)^[5]
Dosage:	1 nmol, 3 nmol, 10 nmol
Administration:	Intracerebroventricularly injection (i.c.v.)
Result:	Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg).

体内研究

DL-TBOA (10 nmol; i.c.v., rats) significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion^[5].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (180-250 g)^[5]
Dosage:	1 nmol, 3 nmol, 10 nmol
Administration:	Intracerebroventricularly injection (i.c.v.)
Result:	Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg).

性状

Solid

溶解性数据

In Vitro:

DMSO : 200 mg/mL (836.05 mM; Need ultrasonic)

H₂O : 5 mg/mL (20.90 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.1803 mL	20.9013 mL	41.8025 mL
5 mM	0.8361 mL	4.1803 mL	8.3605 mL
10 mM	0.4180 mL	2.0901 mL	4.1803 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 5 mg/mL (20.90 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (20.90 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 5 mg/mL (20.90 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (20.90 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 5 mg/mL (20.90 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (20.90 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。